Reversal of Rivaroxaban and Dabigatran by Prothrombin Complex Concentrate: A Randomized, Placebo-Controlled, Crossover Study in Healthy Subjects
@article{Eerenberg2011ReversalOR, title={Reversal of Rivaroxaban and Dabigatran by Prothrombin Complex Concentrate: A Randomized, Placebo-Controlled, Crossover Study in Healthy Subjects}, author={E. Eerenberg and P. Kamphuisen and M. Sijpkens and J. Meijers and H. Buller and M. Levi}, journal={Circulation}, year={2011}, volume={124}, pages={1573–1579} }
Background— Rivaroxaban and dabigatran are new oral anticoagulants that specifically inhibit factor Xa and thrombin, respectively. Clinical studies on the prevention and treatment of venous and arterial thromboembolism show promising results. A major disadvantage of these anticoagulants is the absence of an antidote in case of serious bleeding or when an emergency intervention needs immediate correction of coagulation. This study evaluated the potential of prothrombin complex concentrate (PCC… CONTINUE READING
Paper Mentions
1,328 Citations
Effect of non-specific reversal agents on anticoagulant activity of dabigatran and rivaroxaban: a randomised crossover ex vivo study in healthy volunteers.
- Medicine
- Thrombosis and haemostasis
- 2012
- 518
- Highly Influenced
- PDF
Reversal of rivaroxaban-induced anticoagulation with prothrombin complex concentrate, activated prothrombin complex concentrate and recombinant activated factor VII in vitro.
- Chemistry, Medicine
- Thrombosis research
- 2014
- 90
Therapy with activated prothrombin complex concentrate is effective in reducing dabigatran-associated blood loss in a porcine polytrauma model.
- Medicine
- Thrombosis and haemostasis
- 2016
- 33
Thrombotic safety of prothrombin complex concentrate (Beriplex P/N) for dabigatran reversal in a rabbit model.
- Medicine
- Thrombosis research
- 2014
- 14
Evaluation of Prothrombin Complex Concentrate and Recombinant Activated Factor VII to Reverse Rivaroxaban in a Rabbit Model
- Medicine
- Anesthesiology
- 2012
- 195
- PDF
More efficient reversal of dabigatran inhibition of coagulation by activated prothrombin complex concentrate or recombinant factor VIIa than by four-factor prothrombin complex concentrate.
- Medicine
- Thrombosis research
- 2015
- 32
- PDF
Prothrombin Complex Concentrate Is Effective in Treating the Anticoagulant Effects of Dabigatran in a Porcine Polytrauma Model
- Medicine
- Anesthesiology
- 2015
- 33
Reversal of novel oral anticoagulants in patients with major bleeding
- Medicine
- Journal of Thrombosis and Thrombolysis
- 2013
- 83
- Highly Influenced
Edoxaban Effects on Bleeding Following Punch Biopsy and Reversal by a 4-Factor Prothrombin Complex Concentrate
- Medicine
- Circulation
- 2015
- 201
- PDF
References
SHOWING 1-10 OF 36 REFERENCES
Dabigatran etexilate--a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity.
- Medicine
- Thrombosis and haemostasis
- 2010
- 1,312
- PDF
Ability of Recombinant Factor VIIa to Reverse the Anticoagulant Effect of the Pentasaccharide Fondaparinux in Healthy Volunteers
- Medicine
- Circulation
- 2002
- 295
- PDF
Oral rivaroxaban for symptomatic venous thromboembolism.
- Medicine
- The New England journal of medicine
- 2010
- 1,981
- PDF
Role of prothrombin complex concentrates in reversing warfarin anticoagulation: A review of the literature
- Medicine
- American journal of hematology
- 2008
- 333
- PDF
Dabigatran versus warfarin in the treatment of acute venous thromboembolism.
- Medicine
- The New England journal of medicine
- 2009
- 1,998
- PDF
Effects of the Oral, Direct Factor Xa Inhibitor Rivaroxaban on Platelet‐Induced Thrombin Generation and Prothrombinase Activity 1
- Chemistry, Medicine
- Journal of clinical pharmacology
- 2007
- 130
Pharmacokinetic Profile of the Oral Direct Thrombin Inhibitor Dabigatran Etexilate in Healthy Volunteers and Patients Undergoing Total Hip Replacement
- Medicine
- Journal of clinical pharmacology
- 2005
- 268
Clinical Pharmacokinetics and Pharmacodynamics of the Oral Direct Thrombin Inhibitor Dabigatran Etexilate
- Medicine
- Clinical pharmacokinetics
- 2008
- 596
Effect of recombinant factor VIIa on melagatran-induced inhibition of thrombin generation and platelet activation in healthy volunteers.
- Medicine
- Thrombosis and haemostasis
- 2004
- 91
Dabigatran versus enoxaparin for prevention of venous thromboembolism after hip or knee arthroplasty: a pooled analysis of three trials.
- Medicine
- Thrombosis research
- 2010
- 134